drugset / Trial / NCT00863577

Pharmacokinetic Study of Two Oral Bemiparin Formulations

NCT00863577

Phase 1 Completed 102 enrolled Rovi Pharmaceuticals Laboratories
Parallel-groupOpen-label

Summary

The primary pharmacokinetic analysis will be the correlation of the AUC amidolytic anti-Xa activity

Timeline

Start
2009-03
Primary completion
2010-12
Completion
2011-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Bemiparin Other / unclassified Oral

Indications

No indication recorded.